Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?. (July 2016)

• Record Type: Journal Article
• Authors: Gargiulo, Piera; Della Pepa, Chiara; Berardi, Simona; Califano, Daniela; Scala, Stefania; Buonaguro, Luigi; Ciliberto, Gennaro; Brauchli, Peter; Pignata, Sandro
• Is Part Of: Cancer treatment reviews. Volume 48(2016)
• Page Start: 61
• Page End: 68
• Publication Date: 2016-07
• Subjects: Endometrial Cancer -- POLE-ultramutated -- MSI-hypermutated -- PD-1/PD-L1 axis -- Immunotherapy -- Tumor Infiltrating Lymphocytes (TILs); Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2016.06.008
• Languages: English
• ISSNs: 0305-7372

Abstract

Highlights: Survival of advanced EC is a challenge and new treatment modalities are needed. EC is an immunogenic tumor, and immunotherapy might be a promising option. Genotype studies showed different immune microenvironment in EC subtypes. Blocking PD-1/PD-L1 axis could reduce the cancer-induced immunosuppression. POLE-ultramutated, and MSI-hypermutated might most benefit from immunotherapy. Abstract: Endometrial Cancer (EC) is still a challenge for gynecological oncologists because the treatment of the advanced disease remains an unmet need for patients. The Cancer Genome Atlas Research Network (TCGA) recently provided a comprehensive genomic and transcriptomic analysis of EC, offering a new classification of the disease, based on genetic features, which defines four subgroups of cancer rather than the two traditionally recognized. In the molecular classification two types of EC, the polymerase epsilon (POLE)-ultramutated and the microsatellite instability (MSI)-hypermutated, seem to present an enhanced immune microenvironment and a high mutation burden. The blockade of the immune checkpoints is an innovative approach that has largely demonstrated to be effective in solid malignancies, such as lung, renal and melanoma; it acts by reducing the cancer-induced immune-suppression through inhibition of the PD-1/PD-L1 (Programmed Death and PD-Ligand) axis. All available evidence supporting an over-expression of the PD-1/PD-L1 pathway in EC has been reviewed. In particular in the POLE and MSI ECs an up-regulation of this pathway was found, aiming to suggest a rationale for testing the PD-1/PD-L1 immunotherapy in these cancer subgroups.